Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma
Conditions
- Cancer
- Hematologic Malignancies
- Multiple Myeloma
- Oncology
- Bone Metastases
- Multiple Myeloma Bone Lesions
Interventions
- DRUG: Denosumab
- DRUG: Zoledronic acid
- DRUG: Placebo to Denosumab
- DRUG: Placebo to zoledronic acid
- DRUG: Denosumab (for the open-label treatment phase)
Sponsor
Amgen
Collaborators